On March 11, 2022, the U.S. Food and Drug Administration (FDA) approved Myriad Genetics, Inc.'s BRACAnalysis® CDx test for use as a companion diagnostic to identify patients with germline BRCA-mutated (gRBCAm) human epidermal growth factor receptor 2 (HER2)-negative, high-risk, early-stage breast cancer who may benefit from Lynparza® (olaparib) (AstraZeneca).
Read the Myriad Genetics, Inc. announcement.
Posted 3/14/2022
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
